Pharmaceutical major Lupin Limited reported a 39.5 per cent increase in net profit to ₹855.2 crore for the quarter ended December 31, 2024, driven by robust performance in its North American and European markets. The Mumbai-based drugmaker’s revenue rose 10.6 per cent to ₹5,618.6 crore compared to the same quarter last year.
The shares of Lupin Limited were trading at ₹2,062.15 down by ₹5.45 or 0.26 per cent on the NSE today at 12.50 pm.
The company’s North American sales, which account for 38 per cent of global revenue, grew 12.3 per cent to ₹2,121.3 crore. US sales reached $235 million, up from $212 million in the year-ago period. Lupin maintains its position as the third-largest pharmaceutical player in the US generics market by prescriptions.
The EBITDA margin improved to 25.1 per cent from 21 per cent in the corresponding quarter, while R&D investment increased to ₹434.4 crore, representing 7.7 per cent of sales.
In India, which contributes 34 per cent of global sales, the company recorded an 11.9 per cent growth to ₹1,930.5 crore. The EMEA region showed strong performance with a 20.9 per cent growth to ₹624.9 crore.
During the quarter, Lupin received six ANDA approvals from the US FDA and launched two products in the US market. The company currently has 163 generic products in the US and maintains market leadership in 50 of its marketed generics.